CYRX
NASDAQ · Life Sciences Tools & Services
Cryoport Inc
$9.21
-0.01 (-0.11%)
Financial Highlights (FY 2026)
Revenue
180.57M
Net Income
80.25M
Gross Margin
47.1%
Profit Margin
44.4%
Rev Growth
-9.5%
D/E Ratio
0.37
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 47.1% | 47.1% | 39.0% | 39.0% |
| Operating Margin | -20.9% | -18.8% | 22.9% | 18.0% |
| Profit Margin | 44.4% | 42.2% | 14.0% | 17.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 180.57M | 199.41M | 137.31M | 144.41M |
| Gross Profit | 85.12M | 94.00M | 53.62M | 56.39M |
| Operating Income | -37,720,227 | -37,491,114 | 31.39M | 25.95M |
| Net Income | 80.25M | 79.77M | 19.23M | 25.18M |
| Gross Margin | 47.1% | 47.1% | 39.0% | 39.0% |
| Operating Margin | -20.9% | -18.8% | 22.9% | 18.0% |
| Profit Margin | 44.4% | 42.2% | 14.0% | 17.4% |
| Rev Growth | -9.5% | -9.5% | +13.1% | +7.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 59.39M | 59.39M | 221.73M | 216.61M |
| Total Equity | 159.23M | 159.23M | 262.41M | 301.43M |
| D/E Ratio | 0.37 | 0.37 | 0.84 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -12,193,397 | -12,792,630 | 43.82M | 47.91M |
| Free Cash Flow | — | — | 11.97M | 10.29M |